Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737282 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
A Phase 3 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT00737282 is a Phase 3 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 175 participants.
The verdict
NCT00737282, a Phase 3 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated.
Interventions
- DRUG Proellex 25 mg
- DRUG Proellex 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737282
The ClinicalTrials.gov registry entry for NCT00737282 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Proellex 25 mg is the first listed.
NCT00737282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00737282 about?
NCT00737282 is a clinical study titled "Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids". The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated.
What is the current status of trial NCT00737282?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2008-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00737282?
The interventions under investigation include: Proellex 25 mg (DRUG), Proellex 50 mg (DRUG).
Who is sponsoring clinical trial NCT00737282?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.